FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program

  PTC Therapeutics (NASDAQ: PTCT) announced today that the FDA has granted Fast Track designation to the PTC518 program for the treatment of Huntington's disease. Fast Track designation is awarded to promising therapies for diseases of high unmet need.

"The granting of Fast Track designation to the PTC518 program further supports the potential of PTC518 to provide a disease modifying therapy to Huntington's disease patients," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "We look forward to working collaboratively with FDA to continue to advance the program as efficiently as possible."

PTC518 was discovered using PTC's innovative splicing platform, following the successful discovery and development of Evrysdi® (risdiplam) for the treatment of spinal muscular atrophy.

https://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-to-ptc518-huntingtons-disease-program-302259617.html